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Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin 47 
(collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary 48 
existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, 49 
and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with 50 
allergen-IgE interaction and suppress basophil and mast cell activation. However, it is now 51 
becoming evident that SP-D is likely to be an innate immune surveillance molecule against 52 
tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived 53 
from allergic patients and a leukemic cell line via p53 pathway. Recently, SP-D has been shown 54 
to suppress lung cancer progression via interference with the epidermal growth factor signaling. 55 
In addition, a truncated form of recombinant human SP-D has been reported to induce apoptosis 56 
in pancreatic adenocarcinoma via Fas-mediated pathway in a p53-independent manner. To 57 
further establish a correlation between SP-D presence/levels and normal and cancer tissues, we 58 
performed a bioinformatics analysis, using Oncomine dataset and the survival analysis platforms 59 
Kaplan-Meier plotter, to assess if SP-D can serve as a potential prognostic marker for human 60 
lung cancer, in addition to human gastric, breast and ovarian cancers. We also analyzed 61 
immunohistochemically the presence of SP-D in normal and tumor human tissues. We conclude 62 
that (1) in the lung, gastric and breast cancers, there is a lower expression of SP-D than normal 63 
tissues; (2) in ovarian cancer, there is a higher expression of SP-D than normal tissue; and (3) in 64 
lung cancer, the presence of SP-D could be associated with a favorable prognosis. On the 65 
contrary, at non-pulmonary sites such as gastric, breast and ovarian cancers, the presence of SP-66 
D could be associated with unfavorable prognosis. Correlation between the levels of SP-D and 67 
overall survival requires further investigation. Our analysis involves a large number of dataset; 68 
therefore, any trend observed is reliable. Despite apparent complexity within the results, it is 69 
evident that cancer tissues that produce less levels of SP-D compared to their normal tissue 70 
counterpart, are probably less susceptible to SP-D-mediated immune surveillance mechanisms 71 






INTRODUCTION  77 
Surfactant protein D (SP-D) is a collagenous glycoprotein encoded by SFTPD gene belonging to 78 
the collectins family (1). Like other members of the collectin family, SP-D has a primary subunit 79 
structure that comprises of an N-terminal cysteine-rich region, a triple-helical collagen-like 80 
domain, an α-helical coiled neck domain, and a C-terminal C-type lectin domain (also called 81 
carbohydrate recognition domain (CRD) (2). Each subunit of human SP-D comprises three 82 
identical polypeptide chains of 43 kDa, which is assembled into a tetrameric structure with 4 of 83 
the homotrimeric subunits linked via their N-terminal regions, but trimers, dimers and monomers 84 
also exist. Tetrameric structures can undergo further oligomerization to give SP-D multimers that 85 
could contain up to 96 individual chains. SP-D was originally described in association with 86 
pulmonary surfactant; in the lung, it is synthesized and secreted by type II alveolar cells and non-87 
ciliated bronchiolar epithelial cells. It has a key role in the maintenance of surfactant homeostasis 88 
by reducing surface tension (3). Reduced SP-D expression or genetic variations (single 89 
nucleotide polymorphism) have been associated with an increased risk of respiratory diseases (4, 90 
5).  91 
Extra-pulmonary existence of SP-D has also been reported. SP-D is also expressed by 92 
epithelial cells lining various exocrine ducts, the mucosa of the gastrointestinal and genitourinary 93 
tracts, the nasal cavity and in the brain (2). Furthermore, its presence has been demonstrated in 94 
healthy lacrimal gland, conjunctiva, cornea, and nasolacrimal duct samples (6). Other studies 95 
have shown the presence of SP-D in synovial fluid derived from patients with rheumatoid 96 
arthritis (7).  97 
In addition to its role in surfactant homeostasis, SP-D has a critical function as a regulator 98 
of inflammation (3). In addition to its involvement in the recognition and neutralization of 99 
pathogens which promotes aggregation/agglutination and inhibition of microbial growth (8), SP-100 
D is implicated in the clearance of necrotic and apoptotic cells (9). Thus, its function in the 101 
recognition of non-self and altered self makes it a potent and versatile humoral pattern 102 
recognition receptor (PRR) (10, 11). Furthermore, this molecule is able to inhibit the IL-12p40 103 
production by macrophages (12). SP-D has also been described as a potent link between innate 104 
and adaptive immune mechanisms also participates in the adaptive immune response (13-15). 105 
Studies involving in vivo and ex vivo models of allergic inflammation revealed that SP-D can 106 
alleviate pulmonary hypersensitivity via suppression of IgE levels, promotion of Th2 to Th1 107 
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polarization (16), apoptosis induction in sensitized eosinophils via p53-mediated pathway (17), 108 
and inhibition of IgE synthesis by B cells (18). These studies highlighted a potential role of SP-D 109 
as an immune surveillance molecule. It has recently been shown that SP-D also plays a role in 110 
the control of lung cancer progression via epidermal growth factor signaling (19). Very recently, 111 
Kaur et al have shown that a recombinant fragment of human SP-D, composed of homotrimeric 112 
neck and C-type lectin domains, can induce apoptosis in pancreatic adenocarcinoma cell lines, 113 
such as Panc-1 (p53mt), MiaPaCa-2 (p53mt), and Capan-2 (p53wt), via Fas-mediated pathway 114 
(20).  115 
In the current study, we performed a bioinformatics analysis in order to investigate 116 
whether SP-D can serve as a potential prognostic marker for human lung cancer. We extended 117 
our investigation to several non-pulmonary sites such as human gastric, breast and ovarian 118 
cancer. We used the Oncomine dataset and the survival analysis platforms Kaplan-Meier plotter. 119 
Our results appear to suggest a likely pro-tumorigenic role of SP-D in gastric, breast and ovarian 120 
cancers and an anti-tumor effect in lung cancer. Furthermore, we analyzed the presence of SP-D 121 
in normal and tumor human tissues via immunohistochemistry. Differential expression of SP-D 122 
was also investigated in human cells isolated from normal and tumour ovary tissues by Real-123 
Time PCR. This in silico study, if validated via a retrospective study at the protein level, could 124 




MATERIALS AND METHODS  128 
Oncomine database analysis  129 
The expression level of SFTPD gene in various types of cancer was analyzed using Oncomine 130 
(www.oncomine.org), a cancer microarray database and web-based data mining platform for a 131 
new discovery from genome-wide expression analyses (21, 22). We compared the differences in 132 
mRNA level between normal tissue and cancer. The mRNA expression level in neoplastic tissues 133 
compared to the healthy tissues was obtained as the parameters of p-value < 0.001, fold change > 134 
all, and gene ranking in the top 10%. Information about the datasets used in this study is 135 
summarized in Table I.  136 
 137 
Kaplan-Meier plotter database analysis  138 
A Kaplan-Meier plotter database can assess the effect of 54,675 genes on survival using 10,461 139 
cancer samples (5,143 breast, 1,816 ovarian, 2,437 lung and 1,065 gastric cancer patients with a 140 
mean follow-up of 69/40/49/33 months) using probe sets on the HGU133 Plus 2.0 array. The 141 
prognostic significance of SP-D expression and survival in breast, ovarian, lung and gastric 142 
cancer was analyzed by Kaplan-Meier plotter (www.kmplot.com) (23). The hazard ratio with 143 
95% confidence intervals and logrank p-value was also computed.  144 
 145 
Patients and Specimens  146 
8 fresh clinical specimens (4 normal ovarian epithelial tissues and 4 malignant ovarian epithelial 147 
tumour tissues) were obtained from the Department of Gynaecology of IRCCS “Burlo 148 
Garofolo”, in Trieste, Italy between 2016 and 2017. Oncological patients underwent laparoscopy 149 
for diagnosis of pelvic mass whereas control patients underwent laparoscopy for other 150 
indications. Tissue samples from patients were collected after informed consent following 151 
approval of the ethical considerations by the Institutional Board of IRCCS “Burlo Garofolo”, 152 
Trieste, Italy.  153 
 154 
Immunohistochemical analysis  155 
For the immunohistochemical analysis, human normal and neoplastic tissues, including lung, 156 
breast, ovary and stomach samples, were selected from the archives of the Department of 157 
Pathology, University of Palermo. Immunohistochemistry (IHC) was performed using a polymer 158 
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detection method. Briefly, tissue samples were fixed in 10% v/v buffered formalin and then 159 
paraffin embedded. 4 µm -thick tissue sections were deparaffinized and rehydrated. The antigen 160 
unmasking technique was carried out using Novocastra Epitope Retrieval Solutions, pH 9 (Leica 161 
Biosystems) in a PT Link pre-treatment module (Dako) at 98°C for 30 minutes. Sections were 162 
then brought to room temperature (RT) and washed in PBS. After neutralization of the 163 
endogenous peroxidase with 3% v/v H2O2 and Fc blocking by a specific protein block 164 
(Novocastra, Leica Biosystems), samples were incubated overnight at 4°C with rabbit anti-165 
human SP-D (dilution 1:300) polyclonal antibodies (MRC Immunochemistry Unit, Oxford, UK). 166 
Staining was revealed via polymer detection kit (Novocastra, Leica Biosystems) and AEC (3-167 
amino-9-ethylcarbazole, Dako, Denmark) substrate-chromogen. Slides were counterstained with 168 
Harris Haematoxylin (Novocastra, Leica Biosystems). Sections were analysed under the Axio 169 
Scope A1 optical microscope (Zeiss) and microphotographs were collected through the Axiocam 170 
503 colour digital camera (Zeiss) using the Zen2 software.  171 
 172 
Cell isolation and culture  173 
Carcinoma cells (OvCa) and normal epithelial ovarian cells (OvEp) were isolated from biopsies 174 
derived from ovarian tissue. The tissue was finely minced with a cutter, incubated with a 175 
digestion solution composed by 0.5% trypsin (Sigma-Aldrich, Milan, Italy) and 50 µg/ml DNase 176 
I (Roche, Milan, Italy) in Hanks’ Balanced Salt solution with 0.5mM Ca2+Mg2+ (Sigma-Aldrich) 177 
overnight at 4°C. Next, the enzymatic solution was changed with collagenase type 1 (1.5 mg/ml) 178 
(Worthington Biochemical Corporation, DBA) diluted in Medium 199 with Hank’s salts 179 
(Euroclone Spa, Milan, Italy) for 30 min at 37°C. The digestion was blocked with 10% v/v fetal 180 
bovine serum (FBS, GIBCO, Life Technology) and the cell suspension was filtered through a 181 
100 µm pore filter (BD Biosciences, Italy). The cells were seeded in a 25 cm2 flask, coated with 182 
bovine gelatine, and cultured using Human Endothelial cells serum-free medium (HESF, Life 183 
Technologies), 10% heat-inactivated FBS supplemented with EGF (10 ng/ml), basic FGF (20 184 
ng/ml) and Penicillin-Streptomycin (Sigma-Aldrich). Fresh medium was replaced every 2-3 185 
days. The cells were maintained at 37°C in humidified atmosphere with 5% v/v CO2 and used at 186 




RNA isolation, cDNA synthesis and Quantitative Real-Time PCR (qPCR)  190 
Total RNA was extracted from cells using EuroGOLD trifast (Euroclone), according to the 191 
manufacturer’s instructions, and reverse-transcribed as previously described (32). Quantitative 192 
Real-Time PCR (qPCR) was carried out using a Rotor-Gene 6000 (Corbett, Qiangen, Ancona, 193 
Italy) using iQ SYBR Green Supermix (Applied Biosystems, Milan, Italy). The sequences of the 194 
primers used for amplification of TataBox Binding Protein (TBP) housekeeping gene are: 195 
Forward 5’-GAGCCAAGAGTGAAGAACAGTC-3’; Reverse 5’-196 
GCTCCCCACCATATTCTGAATCT-3’. The sequences of SP-D primers are: Forward 5’-197 
AGGCTGCTTTCCTGAGCATGAC-3’; Reverse 5’-CCATTGGTGAAGATCTCCACACAG-198 
3’. The melting curve was recorded between 55°C and 99°C with a hold every 2s. The relative 199 
amount of gene production in each sample was determined by the Comparative Quantification 200 
(CQ) method supplied as part of the Rotor Gene 1.7 software (Corbett Research) (34). The 201 
relative amount of each gene was normalized with TBP and expressed as arbitrary units (AU) 202 
considering 1 AU obtained from fully differentiated macrophage used as calibrator.  203 
 204 
Statistical analysis  205 
Survival curves were generated by the Kaplan-Meier plots. All results are displayed with p 206 
values from a logrank test. P-values < 0.05 were considered significant. Similarly, with 207 
Oncomine, the statistical significance of data (p-values) was provided by the program.  208 
 209 
RESULTS  210 
Clinical significance of SP-D expression in lung cancer  211 
We initially compared the differences in the mRNA level of SP-D between neoplastic and 212 
healthy tissues using the Oncomine platform. While analyzing Bhattacharjee’s, Hou’s and 213 
Garber’s datasets, we detected a significantly lower SP-D mRNA expression in lung 214 
adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell carcinoma and tumor 215 
carcinoid, compared to the normal lung tissue (Figure 1A, p<0.05; Supplemental Figure S1, 216 
p<0.05). We subsequently performed a bioinformatic analysis of SP-D mRNA expression using 217 
the Kaplan-Meier plotter dataset. As shown in Figure 1B, SP-D mRNA expression was 218 
positively related to an overall survival rate of the patients with lung cancer, stratified into lung 219 
adenocarcinoma and squamous cell carcinoma (p<0.05).  220 
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Immunohistochemical staining for SP-D confirmed a differential expression in healthy 221 
and neoplastic pulmonary parenchyma. Moreover, in lung adenocarcinoma and squamous cell 222 
lung carcinoma tissues, we observed a lower expression of SP-D within its microenvironment 223 
compared to the healthy pulmonary parenchyma (Figure 2).  224 
 225 
Pathological significances of SP-D mRNA expression in gastric, breast and ovarian cancers  226 
The bioinformatics analysis on SP-D mRNA expression in gastric cancer via Cho’s and 227 
DErrico’s datasets showed its higher expression in healthy gastric mucosa compared to its 228 
malignant counterpart, stratified into intestinal, diffuse, and mixed-type adenocarcinoma by 229 
Lauren’s classification (Figure 3A, p<0.05; Supplemental Figure S2, p<0.05). According to the 230 
data from Kaplan-Meier plotter, SP-D mRNA expression was negatively related to an overall 231 
survival rate of the patients with gastric cancer (Figure 3B, p<0.05). If stratified by Lauren’s 232 
classification, SP-D mRNA expression had a statistically significant association with intestinal-233 
type adenocarcinoma, whereas no association with diffuse- and mixed-type adenocarcinomas 234 
was found (Figure 3C, p<0.05). A higher expression of SP-D was negatively correlated with an 235 
overall survival rate in the patients without distant metastasis, Her2-negative and only intestinal-236 
type adenocarcinoma (Figure 3D, p<0.05).  237 
The information regarding the SP-D mRNA expression in breast cancer was obtained 238 
from Zhao’s, TCGA’s and Curtis’s datasets, which showed that SFTPD was expressed at a lower 239 
level in invasive ductal breast carcinoma, male breast carcinoma and breast phyllodes tumor, 240 
compared to normal breast tissues (Figure 4A, p<0.05; Supplemental Figure S3A, p<0.05). 241 
According to the data from Kaplan-Meir plotter, SFTPD expression was negatively linked to the 242 
high overall survival rate in breast cancer patients with Luminal-A grade-1 and grade-2 cancers 243 
(Figure 4B, p<0.05; Supplemental Figure S3B, p<0.05). No correlation between SP-D mRNA 244 
expression and overall survival rate was observed in patients with the other characteristics 245 
(Luminal-B, HER2+, Basal, grade-3, mutated p53, wild-type p53).  246 
Using immunohistochemistry, we observed a variable presence and distribution of SP-D 247 
in normal tissues with respect to their cancer counterpart. In fact, immunohistochemical analysis 248 
performed on either healthy or neoplastic gastric mucosa highlighted a significantly reduced 249 
expression of SP-D in the intestinal-type adenocarcinoma compared to gastric control tissue 250 
(Figure 5A and C). Likewise, a higher expression of SP-D in the normal mammary parenchyma 251 
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was detected compared to that observed within microenvironment within the invasive ductal 252 
breast carcinoma, Luminal-A (Figure 5B and D).  253 
We collected the results from Yoshihara’s and TCGA’s datasets and analyzed SFTPD 254 
expression in ovarian cancer. We highlighted a lower expression of SFTPD mRNA expression in 255 
normal ovary than in serous cystadenocarcinoma (Figure 6A, p<0.05). The Kaplan-Meier plotter 256 
data, derived from stage -1 and -2 patients, showed a negative ratio between SFTPD expression 257 
and either overall or progression-free survival rates of patients with serous cystadenocarcinoma 258 
(Figure 6B, p<0.05). However, no correlation was observed between SFTPD expression and 259 
these parameters (overall or progression-free survival rates) of patients with stage -3 and -4 260 
ovarian cancer.  261 
 262 
Prevalence of SP-D expression in the microenvironment of ovarian cancer 263 
The mRNA expression of SP-D has been also evaluated by Real Time PCR in primary cells 264 
isolated from 4 samples of human ovarian serous cystadenocarcinoma and 4 samples of normal 265 
ovarian tissues. As shown in figure 7A, the cells isolated from ovarian serous 266 
cystoadenocarcinoma tissues expressed more SP-D compared to the normal tissue, confirming 267 
the data obtained with the bioinformatics analysis. Immunohistochemical analysis also revealed 268 
the presence and the distribution of SP-D in the normal ovary where it appeared to be localized 269 
in the ovarian epithelium lining and in the serous cystadenocarcinoma. In addition, we detected 270 
differential expression in the normal and its malignant histotypes. Moreover, in the ovarian 271 
context, it showed an enrichment of SP-D expressing cells within the tumor microenvironment 272 
compared to the control tissue (Figure 7B and C).  273 
 274 
DISCUSSION  275 
The importance of SP-D in the regulation of the inflammation and homeostasis and in the 276 
protection against infection and allergens in the lung and at a range of extra-pulmonary sites is 277 
well documented (24, 25). However, there are recent evidences to implicate SP-D as an immune 278 
surveillance molecule against cancer (19, 20). In this study, we examined the potential 279 
prognostic value of this protein in lung, gastric, breast and ovarian cancers. We focused our 280 
attention on these tumor types because we performed a bioinformatics analysis using the Kaplan-281 
Meier plotter dataset, a manually curated database containing the information of 54,675 genes on 282 
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5,143 breast, 1,816 ovarian, 2,437 lung and 1,065 gastric cancer samples. This is the most 283 
updated and reliable dataset available that offers the possibility of stratifying the analysis based 284 
on different tumor settings. The bioinformatics analysis highlighted a favorable prognostic effect 285 
of SP-D mRNA expression in the lung cancer, both in adenocarcinoma and squamous cell 286 
carcinoma; on the contrary, an unfavorable prognostic effect in gastric, ovarian and breast cancer 287 
was revealed. In particular, SP-D mRNA expression showed a negative correlation with the 288 
intestinal-type gastric adenocarcinomas, grade-1 and grade-2 breast cancers and with stage -1 289 
and -2 ovarian cancers. No significant correlation was showed with stage -3 and -4 in breast and 290 
ovarian cancers. 291 
Sin et al (26) have suggested earlier that low SP-D levels may be correlated to the 292 
development of lung cancer. They observed a reduction of the concentration of SP-D in the 293 
bronchoalveolar lavage fluid of heavy smokers that was linked to bronchial dysplasia. More 294 
recently, Hasegawa et al (19) showed the presence of SP-D in lung cancer and demonstrated that 295 
SP-D was able to interfere, via its CRD region, with the interaction between epidermal growth 296 
factor (EGF) to EGF receptor (EGFR), a tyrosine kinase receptor of the ErbB family, causing 297 
downregulation of the EGF induced signaling (19). This receptor is commonly altered in 298 
epithelial tumors and its dysregulation leads to cell proliferation, angiogenesis, invasion, and 299 
metastasis (27). Furthermore, it has been recently demonstrated that SP-D is also able to interact 300 
with the mutant form of EGFR, inhibiting its ligand-independent dimerization (27). Very 301 
recently, Kaur et al have reported the ability of a recombinant form of human SP-D to induce 302 
apoptosis via TNF-α/Fas-mediated pathway in human pancreatic adenocarcinoma using Panc-1 303 
(p53mt), MiaPaCa-2 (p53mt), and Capan-2 (p53wt) cell lines. Treatment of these cell lines with a 304 
recombinant form of truncated human SP-D (made up of neck and C-type lectin domains only) 305 
for 24 h caused growth arrest in G1 cell cycle phase and triggered transcriptional upregulation of 306 
pro-apoptotic factors such as TNF-α and NF-κB. Translocation of NF-κB from the cytoplasm 307 
into the nucleus of pancreatic cancer cell lines was observed following treatment with SP-D. SP-308 
D treatment caused upregulation of pro-apoptotic marker Fas, which then triggered cleavage of 309 
caspase 8 and 3. This study raises the possibility of using recombinant SP-D as a therapeutic 310 
molecule against pancreatic cancer irrespective of their p53 phenotype (20). 311 
The EGFR is commonly overexpressed in non-small cell lung cancer (in 89% squamous 312 
cell carcinoma; 41% adenocarcinomas) (28), and therefore, it is considered a potential target for 313 
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cancer therapy (28); the presence of SP-D in these cancers could exert a protective role via 314 
downregulation of the EGFR pathway. It has also been shown that serum level of SP-D reflects 315 
its levels in the lung and that higher amount of SP-D in the serum correlated with better overall 316 
survival in patients with EGFR mutant adenocarcinoma undergoing treatment with gefitinib, a 317 
tyrosine kinase inhibitor (27).  318 
Our study appears to highlight a more favorable prognosis for adenocarcinoma with 319 
respect to squamous cell carcinoma. A possible explanation of this observation may be that 320 
adenocarcinoma originates from peripheral airways progenitor cells that are able to produce SP-321 
D. Moreover, more SP-D production may be indicative of a more differentiated cancer.  322 
SFTPD, together with a number of genes selectively expressed in the respiratory 323 
epithelial cells, is under the control of the thyroid transcription factor 1 (TTF-1) (29, 30). A 324 
recent meta-analysis showing that TTF-1 overexpression is related to a favorable prognosis for 325 
NSCLC (non-small cell lung carcinoma) patients (31), appears to strengthen the results being 326 
reported here.  327 
Although the overexpression of the EGFR gene has also been reported in a variety of 328 
other cancers including those of head and neck, ovary, cervix, bladder, esophagus, stomach, 329 
brain, breast, endometrium and colon (32), the above-mentioned mechanisms cannot explain the 330 
opposite results obtained via the bioinformatics analysis of Kaplan Mayer dataset for gastric, 331 
ovarian and breast carcinomas, where SP-D showed an unfavorable prognostic effect. We think 332 
that the unfavorable prognostic effect of SP-D in other tumor settings can be due to its direct or 333 
indirect action on the immune population present in the tumor microenvironment (15). The 334 
following mechanisms can explain the role of SP-D in determining a tumor microenvironment 335 
favorable to tumor progression. For example, the protective effect of SP-D against breast cancer 336 
cells can be negated by the presence of hyaluronic acid, which is abundantly present in the 337 
microenvironment of a number of solid tumors (33) (Murugaiah, Bulla and Kishore, unpublished 338 
data). 339 
SP-D is able to reduce the expression of CD11c (15). CD11c is predominantly expressed 340 
on dendritic cells, but also on effector cells in the local tumor microenvironment, such as some 341 
macrophages, natural killer (NK) and activated T cells (34). It has been shown that low CD11c 342 
expression indicates unfavorable prognosis in patients with gastric cancer (35).  343 
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SP-D can promote production of TNF-α and IFN-γ (16, 18, 36). The anti-tumor effects of 344 
Th1 cells may reflect their known role in enhancing CD8+ T cell responses and activating 345 
macrophages, through the secretion of TNF-α and IFN-γ. IFN-γ can increase tumor cell class I 346 
MHC expression and sensitivity to lysis by NK cells and cytotoxic T lymphocytes (CTLs). 347 
Besides, antigen-presenting cells such as macrophages and dendritic cells can directly activate 348 
antigen-specific Th1 or CTLs, which can activate the anti-tumor immune response and are thus 349 
associated with favorable prognosis of patients with many types of cancers (37, 38).  350 
It has been demonstrated that SP-D binds to lymphocytes and suppress T cell 351 
proliferation (14) via apoptosis induction in activated PBMCs. SP-D has been shown to enhance 352 
expression of CTLA-4, a negative regulator of T cell activation and proliferation (39). In 353 
addition, monocytes expressed CTLA-4, but only the lymphocytes treated with SP-D show a 354 
significant overexpression of CTLA-4 (15). There is strong experimental and clinical evidence to 355 
suggest that T cell responses to some tumors are inhibited by the involvement of CTLA-4, one of 356 
the best-defined inhibitory pathways in T cells (40, 41). In fact, tumor-infiltrating T cells often 357 
have a dysfunctional (exhausted) phenotype that is characterized by impaired effector functions 358 
and increased expression of CTLA-4 and other inhibitory molecules (40, 41). Blockade of the 359 
CTLA-4 pathways is now being widely used in the clinic to reverse the dysfunctional phenotype 360 
of tumor-specific T cells and enhance their ability to kill tumor cells (41). In conclusion, SP-D, 361 
increasing the expression of CTLA-4 also may contribute to the inhibition of the anti-tumor 362 
immune responses.  363 
SP-D is able to inhibit the IL-12p40 production by macrophages via the 364 
SIRPα/ROCK/ERK signaling pathway (12). IL-12p40 is a component of IL-12p70 and IL-23, 365 
and its regulation is important for both innate and adaptive immunity. IL-12p40 is a marker of 366 
M1-like macrophages and data indicate that IL-12p40 may be contributing to inducing Th 1 367 
polarization (42, 43). Macrophages derived from IL-12p40 deficient mice have a bias toward 368 
M2-like polarization (42). The production of IL-12p40 by macrophages and dendritic cells is 369 
associated with the ability to migrate to the lymph node and initiate T cell responses (44). We 370 
think that SP-D repressing the expression of IL-12p40 in macrophages may maintain the steady 371 
M2-like polarization and inhibit Th1 polarization.  372 
SP-D is able to interact with the leukocyte-associated Ig-like receptor-1 (LAIR-1) (45), 373 
also known as CD305. This molecule is a transmembrane glycoprotein and is expressed on 374 
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almost all immune cells and CD34+ hematopoietic progenitor cells. SP-D acts as a ligand for the 375 
inhibitory receptor LAIR-1, which inhibits the function of multiple types of immune cells (45) 376 
indicating that SP-D present in the tumour microenvironment may exert its immunomodulatory 377 
effect and inhibit the anti-tumor immune responses through LAIR-1 activation. Thus, the context 378 
of immune infiltration and composition of tumour microenvironment dictate the consequent 379 
effects of SP-D, and hence, tumour progression or resistance. 380 
In summary, our in silico analysis, if confirmed with a retrospective study at the protein 381 
level, could highlight a possible role of SP-D as a novel marker for tumor prognosis in a range of 382 
cancers. The presence of SP-D in cancer could be associated with a favorable prognosis in lung 383 
cancer where it has been demonstrated to downregulate the EGF signaling and unfavorable 384 
prognosis in non-pulmonary sites such as gastric, breast and ovarian cancers. We hypothesized 385 
different possible mechanisms that this molecule could play in the tumor microenvironment on 386 
the basis of the existing knowledge about the interaction of SP-D with the different immune 387 
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139 lung adenocarcinoma, 21 squamous cell lung carcinoma, 20 lung 
carcinoid tumor, 6 small cell lung carcinoma, and 17 normal lung 
samples were analyzed on Affymetrix U95A microarrays. Sample data 
includes type, age, M stage, max tumor percentage, N stage, 
primary/metastatic, recurrence, sex, site of metastasis, smoking rate 





91 non-small cell lung carcinoma and 65 adjacent normal lung samples 






67 lung carcinoma samples of various types and 6 normal lung 
samples were analyzed on cDNA microarrays. Sample data includes 





65 gastric adenocarcinoma, 19 paired surrounding normal tissue, and 
6 gastrointestinal stromal tumor samples were analyzed. Sample data 
includes age, grade, stage, TNM stage, sex, and subgroup. 
mRNA 
 
DErrico Gastric 31 paired gastric carcinoma and adjacent normal gastric mucosa and 7 
unmatched gastric carcinoma samples were analyzed. Sample data 





Normal breast (n=3) and breast carcinoma (n=61) samples were 
analyzed on cDNA microarrays. Sample data includes tumor 
percentage, age, E-Cadherin status, estrogen receptor status, grade, 






532 invasive breast carcinoma, 61 paired normal breast tissue and 3 
paired metastatic samples were analyzed. Sample data includes age, 
histology, TNM stage, ER/PR/ERBB2 status, sex, stage, and others. This 






1,992 breast carcinoma samples and 144 paired normal breast 
samples were analyzed for the METABRIC project. Sample data 
includes ER/PR/ERBB2 status, overall survival status and follow-up 





43 ovarian serous adenocarcinomas and 10 normal peritoneum 
samples were analyzed. Sample data includes cancer sample site, 





586 ovarian serous cystadenocarcinoma samples and 8 normal ovary 
samples were analyzed. Sample data includes age, stage, grade, 
survival, and others. This dataset consists of Level 2 (processed) data 








Figure 1. Pathological significance of SP-D expression in lung cancer. Bhattacharjee’s and 600 
Hou’s datasets were used for bioinformatics analysis to explore SP-D mRNA expression in the 601 
lung cancer. A lower SP-D mRNA expression was detectable in lung adenocarcinoma, squamous 602 
cell carcinoma, large cell carcinoma, small cell carcinoma and tumor carcinoid than in normal 603 
lung tissue (A, p<0.05). According to the data from Kaplan-Meir plotter, SP-D mRNA 604 
expression was positively related to an overall survival rate of the patients with lung cancer, even 605 




















Figure 2. Immunohistochemistry analysis for SP-D in lung. Compared to healthy lung (A – 625 
B) a decreased expression of SP-D in squamous cell carcinoma (C) and adenocarcinoma of the 626 
lung (D) was observed. Polymer detection system with AEC (red) chromogen was used; scale 627 










Figure 3. Pathological significance of SP-D expression in gastric cancer. Cho’s dataset has 637 
explored SP-D mRNA expression in gastric cancer. A lower SFTPD expression was detectable 638 
in gastric cancer than that in normal mucosa, even stratified into diffuse-, intestinal-, and mixed- 639 
type adenocarcinomas by Lauren’s classification (A, p<0.05). According to the data from 640 
Kaplan-Meier plotter, SP-D mRNA expression was negatively related to an overall survival rate 641 
of the patients with gastric cancer (B, p<0.05). If stratified by Lauren’s classification, SP-D 642 
mRNA expression was negatively related to an overall survival rate in the patients with 643 
intestinal-type adenocarcinoma (C, p<0.05), without distant metastasis and Her2-negative (D, 644 







Figure 4. The clinicopathological significances of SP-D expression in breast cancer. Zhao’s 651 
and TCGA’s datasets have revealed that a lower SP-D mRNA expression in invasive ductal 652 
breast carcinoma and male breast carcinoma that in normal breast tissues (A, p<0.05). There was 653 
a negative association between SP-D mRNA expression and a favorable prognosis in the breast 654 
cancer patients with Luminal-A only with grade -1 and -2 cancers, for Kaplan-Meir plotter (B, 655 














Figure 5. Representative Immunohistochemical microphotographs of SP-D expression in 669 
the healthy gastric mucosa (A), and ductal mammary epithelium (B) and their malignant 670 
histotypes intestinal-type gastric adenocarcinoma (C) and invasive ductal breast carcinoma, 671 
Luminal-A (D). a decreased expression of SP-D in the intestinal-type gastric adenocarcinoma 672 
and invasive ductal breast carcinoma, Luminal-A respect to their normal counterparts can be 673 










Figure 6. Pathological significance of SP-D expression in ovarian cancer. Yoshihara’s and 683 
TCGA’s datasets explored SP-D mRNA expression in ovarian cancer. A higher SP-D mRNA 684 
expression was detectable in serous cystadenocarcinoma than that in normal ovary (A, p<0.05). 685 
According to the data from Kaplan-Meir plotter, SP-D mRNA expression showed a negative 686 
relationship both overall or progression-free survival rates of patients with serous 687 
















Figure 7. Figure 7. Quantitative Real-Time PCR analysis of SP-D performed on the normal 703 
ovarian epithelium and the epithelial ovarian tumour (A). Representative microphotographs 704 
showing an enrichment in SP-D positive cells in the serous cystadenocarcinoma (B) compared to 705 
the normal ovarian epithelium (C). Polymer detection system with AEC (red) chromogen; scale 706 









Supplemental Figure S1. SP-D expression in lung cancer. Garber’s dataset has explored SP-D 715 
mRNA expression in the lung cancer. A lower SP-D mRNA expression was detectable in large 716 
cell carcinoma, adenocarcinoma, squamous cell carcinoma and small cell carcinoma than in 717 













Supplemental Figure S2. SP-D expression in gastric cancer. DErrico’s dataset has revealed a 730 














Supplemental Figure S3. Pathological significance of SP-D expression in breast cancer. 744 
Curtis’s dataset has revealed a lower SP-D mRNA expression in phyllodes tumor than in normal 745 
breast tissue. (A, p<0.05). There was a negative association between SP-D mRNA expression 746 
and a favorable prognosis in the breast cancer patients with Luminal-A with grade -1, for 747 
Kaplan-Meir plotter (B, p<0.05). HR, hazard ratio.  748 
 749 
